Adults with type 1 diabetes achieved better glycemic control with the new automated insulin delivery (AID) system than with multiple daily injections (MDI) combined with continuous glucose monitoring (CGM). Results were presented at the European Association for the Study of Diabetes Conference 2025.

This randomized controlled trial included 79 adults aged 18–70 years with type 1 diabetes using MDI and CGM. Participants completed 14 days of MDI+CGM data collection before being randomized 2:1 to automated insulin delivery system + CGM (n=52) or continued MDI+CGM (n=27) for 13 weeks.

After 13 weeks, HbA1c decreased significantly in the AID group versus control (adjusted mean difference -0.8%, 95% CI -1.1 to -0.6; p<0.0001). Time in range (70–180 mg/dL) improved by 23.4% (95% CI 18.8–28.1; p<0.0001). Hypoglycemia below 54 mg/dL and 70 mg/dL remained low. No severe hypoglycemia or diabetic ketoacidosis occurred. Total daily insulin dose and body mass index were unchanged.

The study demonstrated that direct transition from MDI to AID is feasible, safe, and improves glycemic outcomes in adults with type 1 diabetes.